Valneva open to partners for COVID-19 vaccine as it looks beyond Europe yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Here are 10 things to know about Bharat Biotech, its founder Krishna Ella
Ella said Bharat Biotech is investing Rs 100 crore on research and conducting clinical trials in FY2021. In addition, the company will invest up to Rs 200 crore in FY2021 and FY2022 for the development of a greenfield facility for a Covid-19 vaccine.
Krishna Ella, Chairman and Managing Director of Bharat Biotech.
With the restricted use approval of Bharat Biotech s Covid-19 vaccine Covaxin by India, both Bharat Biotech and its founder Chairman and Managing Director Krishna Ella, 73, have hogged the limelight.
Here are 10 things to know about Ella and his company
Valneva’s inactivated COVID-19 vaccine candidate enters Phase 1/2 clinical trial Valneva has started a Phase 1/2 trial of its COVID-19 vaccine: eying up potential regulatory approval in the fourth quarter of 2021. It champions a ‘tried and tested’ approach with its inactivated candidate.
Valneva’s candidate is the only inactivated virus vaccine approach being advanced in Europe and the US. Valneva highlights that an inactivated vaccine candidate has the potential to be used in certain vulnerable patient populations; whereas vaccines using new tech are not being administered to such groups because of lack of data. And it says the reduced distribution complexity is another advantage of inactivated vaccines.
Share:
Saint-Herblain (France), December 16, 2020 – Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
VLA2001 leverages the manufacturing platform of Valneva s licensed Japanese encephalitis vaccine, IXIARO
® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.
The VLA2001-201 study is a randomized, double blind and placebo-controlled trial evaluating the safety and immunogenicity for three dose levels in approximately 150 healthy adults.
The study will be conducted in study sites across the United Kingdom and is supported by the National Institute for Health Research (NIHR).
Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.